Your session is about to expire
← Back to Search
Pembrolizumab + All-Trans Retinoic Acid for Melanoma
Study Summary
This trial is testing a new cancer treatment that combines VESANOID with pembrolizumab.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What are the benefits of Pembrolizumab with All-Trans Retinoic Acid?
"Pembrolizumab with All-Trans Retinoic Acid is most often used to treat melanoma that cannot be surgically removed. This medication can also offer relief for patients with microsatellite instability high, keratinization disorders of the feet, and high risk of recurrence."
Does Pembrolizumab have any previous experience being studied with All-Trans Retinoic Acid?
"Presently, there are 1021 clinical trials researching the efficacy of pembrolizumab with all-trans retinoic acid. Out of these, 127 are in phase 3. Most of the pembrolizumab with all-trans retinoic acid trials are based in Houston, Texas; however, there are 36158 locations operating studies for pembrolizumab with all-trans retinoic acid."
Who might be most helped by taking part in this experiment?
"Eligible patients for this melanoma study must be aged 18-100. A total of 26 patients will be enrolled in the clinical trial."
Is this research study recruiting new participants?
"According to the latest update on clinicaltrials.gov, this particular trial is not searching for new patients. The trial was originally posted on October 31st, 2017 but was updated on November 1st, 2020. There are, however, 1802 other trials that are actively recruiting patients."
Are patients above the age of 20 being recruited for this clinical trial?
"So long as they are over 18 and younger than 100, any adult can sign up for this clinical trial."
Share this study with friends
Copy Link
Messenger